

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM541126

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Intellectual Property Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
scPharmaceuticals Inc.		09/17/2019	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Solar Capital Ltd., as Agent		
Street Address:	500 Park Avenue, 3rd Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10022		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	5351975	SCPHARMACEUTICALS	
Registration Number:	4851675	SCPHARMACEUTICALS	
Registration Number:	5287573	FUROSCIX	
Registration Number:	5291840	SC2WEAR	
CORRESPONDENCE DATA			
Fax Number:	2138918763		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	rhonda.deleon@lw.com		
Correspondent Name:	Latham & Watkins LLP		
Address Line 1:	355 South Grand Avenue		
Address Line 4:	Los Angeles, CALIFORNIA 90071-1560		
ATTORNEY DOCKET NUMBER:	054439-0053		
NAME OF SUBMITTER:	Rhonda DeLeon		
SIGNATURE:	/Rhonda DeLeon/		
DATE SIGNED:	09/17/2019		
Total Attachments: 8			
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page1.tif			
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page2.tif			

OP \$115.00 5351975

source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page3.tif
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page4.tif
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page5.tif
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page6.tif
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page7.tif
source=Solar_scPharmaceuticals - Intellectual Property Security Agreement Executed#page8.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement") dated as of September 17, 2019, is made by scPharmaceuticals Inc., a Delaware corporation, and each domestic Subsidiary signatory hereto (individually and collectively, the "Grantor"), in favor of Solar Capital Ltd., a Maryland corporation ("Agent") in its capacity as collateral agent for the Lenders (as defined below).

RECITALS

A. Grantor has entered into a Loan and Security Agreement with certain financial institutions party thereto (the "Lenders") and Agent, in its capacity as collateral agent for itself and the Lenders, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.


6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of New York, and shall have been accepted by Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

SCPHARMACEUTICALS INC., a Delaware corporation

By  _____

Name: John Tucker

Title: Chief Executive Officer

[Signature Page to Intellectual Property Security Agreement]

TRADEMARK
REEL: 006746 FRAME: 0798

AGENT:

SOLAR CAPITAL LTD., a Maryland corporation

By 
Name: Anthony J. Stokire
Title: Authorized Signatory

[Signature Page to Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Goodwin Docket No.	Country	Application No.	Patent No.
SPM-002AU	Australia	2014248164	
SPM-002BR	Brazil	BR112015025204-4	
SPM-002CA	Canada	2,908,935	
SPM-002CN	China, People's Republic of	201480031207.3	
SPM-002EP	Europe	14778339.3	
SPM-002HK	Hong Kong	16109253.5	
SPM-002IN	India	9291/DELNP/2015	
SPM-002IL	Israel	241917	
SPM-002JP	Japan	2016-506607	6,415,535
SPM-002JPD1	Japan	2018-187299	
SPM-002KR	Korea, Republic of	2015-7031677	
SPM-002MX	Mexico	MX/a/2015/014064	
SPM-002SG	Singapore	11201508251R	11201508251R
SPM-002SGD1	Singapore	10201709388Q	
SPM-002ZA	South Africa	2015/07320	
SPM-002	U.S.	14/781,706	9,884,039
SPM-002D1	U.S.	15/877,865	10,272,064
SPM-002D1C1	U.S.	16/295,085	
SPM-004PR	U.S.	62/799,215	

EXHIBIT C

Trademarks

MARK	CLASS	REGISTRATION NO.	COUNTRY
scPharmaceuticals	10	5351975	US
scPharmaceuticals	5	4851675	US
scPharmaceuticals	5, 10	1346216	WIPO
scPharmaceuticals	5, 10	1346216	EUROPE based on WIPO registration
FUROSCIX	10	5287573	US
FUROSCIX	5	1337899	WIPO
FUROSCIX	5	1337899	EUROPE based on WIPO registration
sc2Wear	10	5291840	US
sc2Wear	10	1340388	WIPO
sc2Wear	10	1340388	EUROPE based on WIPO registration

EXHIBIT D

Mask Works

None.